{"id": "article-25088_0", "title": "Metoclopramide -- Continuing Education Activity", "content": "Metoclopramide is a dopamine receptor antagonist and has been approved by the FDA to treat nausea and vomiting in patients with gastroesophageal reflux disease or diabetic gastroparesis by increasing gastric motility. It is also used to control nausea and vomiting in chemotherapy patients. Additionally, metoclopramide can be administered prophylactically to prevent nausea and vomiting in postoperative patients when nasogastric suction is contraindicated or unavailable and has shown surprising success in treating migraines; however, the FDA has not explicitly approved it for these other conditions. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of metoclopramide, pertinent for interprofessional team members in treating patients with conditions that are of clinical value.", "contents": "Metoclopramide -- Continuing Education Activity. Metoclopramide is a dopamine receptor antagonist and has been approved by the FDA to treat nausea and vomiting in patients with gastroesophageal reflux disease or diabetic gastroparesis by increasing gastric motility. It is also used to control nausea and vomiting in chemotherapy patients. Additionally, metoclopramide can be administered prophylactically to prevent nausea and vomiting in postoperative patients when nasogastric suction is contraindicated or unavailable and has shown surprising success in treating migraines; however, the FDA has not explicitly approved it for these other conditions. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of metoclopramide, pertinent for interprofessional team members in treating patients with conditions that are of clinical value."}
{"id": "article-25088_1", "title": "Metoclopramide -- Continuing Education Activity", "content": "Objectives: Explain the mechanisms of action of metoclopramide. Identify the approved and off-label indications for metoclopramide. Review the potential adverse events associated with metoclopramide. Summarize the contraindications to therapy with metoclopramide. Access free multiple choice questions on this topic.", "contents": "Metoclopramide -- Continuing Education Activity. Objectives: Explain the mechanisms of action of metoclopramide. Identify the approved and off-label indications for metoclopramide. Review the potential adverse events associated with metoclopramide. Summarize the contraindications to therapy with metoclopramide. Access free multiple choice questions on this topic."}
{"id": "article-25088_2", "title": "Metoclopramide -- Indications", "content": "The FDA has approved metoclopramide to treat nausea and vomiting in patients with gastroesophageal reflux disease (in patients\u00a0who fail to respond to established therapy)\u00a0and\u00a0diabetic gastroparesis by increasing gastric motility. [1] [2] Parenteral metoclopramide is also FDA approved to control nausea and vomiting in chemotherapy patients. [3] [4]", "contents": "Metoclopramide -- Indications. The FDA has approved metoclopramide to treat nausea and vomiting in patients with gastroesophageal reflux disease (in patients\u00a0who fail to respond to established therapy)\u00a0and\u00a0diabetic gastroparesis by increasing gastric motility. [1] [2] Parenteral metoclopramide is also FDA approved to control nausea and vomiting in chemotherapy patients. [3] [4]"}
{"id": "article-25088_3", "title": "Metoclopramide -- Indications", "content": "Metoclopramide is used off-label prophylactically to prevent nausea and vomiting in postoperative patients when nasogastric suction is contraindicated or unavailable. It is particularly\u00a0useful in this role because it does not cause any concomitant increase in gastric secretions. [5] Metoclopramide is also used off-label to treat acute migraine in the emergency department. It is an effective adjunctive agent for acute nausea and vomiting and reduces headache intensity; hence it is a valuable agent for the short-term\u00a0treatment of\u00a0acute migraine in the ED.\u00a0It is important to recognize that FDA has not explicitly approved it for acute migraine. Still, it is a valuable alternative to opioids\u00a0due to the potential for opioid\u00a0use disorder. [6] [7]", "contents": "Metoclopramide -- Indications. Metoclopramide is used off-label prophylactically to prevent nausea and vomiting in postoperative patients when nasogastric suction is contraindicated or unavailable. It is particularly\u00a0useful in this role because it does not cause any concomitant increase in gastric secretions. [5] Metoclopramide is also used off-label to treat acute migraine in the emergency department. It is an effective adjunctive agent for acute nausea and vomiting and reduces headache intensity; hence it is a valuable agent for the short-term\u00a0treatment of\u00a0acute migraine in the ED.\u00a0It is important to recognize that FDA has not explicitly approved it for acute migraine. Still, it is a valuable alternative to opioids\u00a0due to the potential for opioid\u00a0use disorder. [6] [7]"}
{"id": "article-25088_4", "title": "Metoclopramide -- Indications", "content": "Metoclopramide can also be used off-label to\u00a0treat hyperemesis gravidarum in pregnant patients; still, it should be used cautiously because of the lack of studies on the effects of the drug in pregnant women. [8] [9] Recent studies have also shown evidence of metoclopramide\u2019s efficacy in treating Diamond Blackfan syndrome. [10] [11] Metoclopramide has also been efficacious in treating nausea in critically ill advanced liver disease patients. [12]", "contents": "Metoclopramide -- Indications. Metoclopramide can also be used off-label to\u00a0treat hyperemesis gravidarum in pregnant patients; still, it should be used cautiously because of the lack of studies on the effects of the drug in pregnant women. [8] [9] Recent studies have also shown evidence of metoclopramide\u2019s efficacy in treating Diamond Blackfan syndrome. [10] [11] Metoclopramide has also been efficacious in treating nausea in critically ill advanced liver disease patients. [12]"}
{"id": "article-25088_5", "title": "Metoclopramide -- Mechanism of Action", "content": "Metoclopramide works by antagonizing central and peripheral dopamine-two receptors (D2) in the medullary chemoreceptor trigger zone in the area postrema, usually stimulated by levodopa or apomorphine. It achieves this by decreasing the sensitivity of visceral afferent nerves that transmit from the gastrointestinal system to the vomiting center in the area postrema in the chemoreceptor trigger zone. [13] In addition to antagonizing dopamine receptors, metoclopramide\u00a0is an antagonist at\u00a05HT3 (type 3 serotonin receptors) and an agonist at\u00a05HT4 receptors. [14] [15] Metoclopramide also blocks the antiperistaltic effects of apomorphine, allowing metoclopramide to slow apomorphine's inhibition of gastric emptying, thereby\u00a0accelerating gastric emptying by increasing the amplitude and duration of esophageal contractions.\u00a0Consequently, it increases the resting tone of the lower esophageal sphincter while simultaneously relaxing the duodenal bulb and pyloric sphincter, thereby\u00a0increasing the peristalsis of the duodenum and jejunum. [16] [17]", "contents": "Metoclopramide -- Mechanism of Action. Metoclopramide works by antagonizing central and peripheral dopamine-two receptors (D2) in the medullary chemoreceptor trigger zone in the area postrema, usually stimulated by levodopa or apomorphine. It achieves this by decreasing the sensitivity of visceral afferent nerves that transmit from the gastrointestinal system to the vomiting center in the area postrema in the chemoreceptor trigger zone. [13] In addition to antagonizing dopamine receptors, metoclopramide\u00a0is an antagonist at\u00a05HT3 (type 3 serotonin receptors) and an agonist at\u00a05HT4 receptors. [14] [15] Metoclopramide also blocks the antiperistaltic effects of apomorphine, allowing metoclopramide to slow apomorphine's inhibition of gastric emptying, thereby\u00a0accelerating gastric emptying by increasing the amplitude and duration of esophageal contractions.\u00a0Consequently, it increases the resting tone of the lower esophageal sphincter while simultaneously relaxing the duodenal bulb and pyloric sphincter, thereby\u00a0increasing the peristalsis of the duodenum and jejunum. [16] [17]"}
{"id": "article-25088_6", "title": "Metoclopramide -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Metoclopramide is rapidly and well absorbed from the gastrointestinal tract, and peak plasma concentrations\u00a0are attained about 1 to 2 hours after the oral dose.\u00a0Metoclopramide is lipid-soluble, giving it a large half-life\u00a0and a large volume of distribution. Its half-life\u00a0can range from 4.5 hours to 8.8 hours. [18] Distribution: The volume of distribution is high (approximately 3.5 L/kg), which suggests the extensive distribution of drugs to the tissues. [19] Metabolism: Metoclopramide is metabolized by\u00a0oxidation primarily via cytochrome P450 2D6 (CYP2D6), glucuronide, and sulfate conjugation. [20]", "contents": "Metoclopramide -- Mechanism of Action -- Pharmacokinetics. Absorption: Metoclopramide is rapidly and well absorbed from the gastrointestinal tract, and peak plasma concentrations\u00a0are attained about 1 to 2 hours after the oral dose.\u00a0Metoclopramide is lipid-soluble, giving it a large half-life\u00a0and a large volume of distribution. Its half-life\u00a0can range from 4.5 hours to 8.8 hours. [18] Distribution: The volume of distribution is high (approximately 3.5 L/kg), which suggests the extensive distribution of drugs to the tissues. [19] Metabolism: Metoclopramide is metabolized by\u00a0oxidation primarily via cytochrome P450 2D6 (CYP2D6), glucuronide, and sulfate conjugation. [20]"}
{"id": "article-25088_7", "title": "Metoclopramide -- Mechanism of Action -- Pharmacokinetics", "content": "Excretion: In a study, approximately 85% of the radioactivity of an orally administered dose is recovered in the urine, and half of it is present as a parent or conjugated metoclopramide. Around 18\u201322% of the dose\u00a0is recovered as free metoclopramide in urine. Metoclopramide's elimination half-life in adults with normal renal function has been reported to be ~ 6 hours. In adults with severe renal impairment, there is a reduced metoclopramide clearance, increasing\u00a0the elimination half-life (7.7\u00a0to 17.8 hours). [14]", "contents": "Metoclopramide -- Mechanism of Action -- Pharmacokinetics. Excretion: In a study, approximately 85% of the radioactivity of an orally administered dose is recovered in the urine, and half of it is present as a parent or conjugated metoclopramide. Around 18\u201322% of the dose\u00a0is recovered as free metoclopramide in urine. Metoclopramide's elimination half-life in adults with normal renal function has been reported to be ~ 6 hours. In adults with severe renal impairment, there is a reduced metoclopramide clearance, increasing\u00a0the elimination half-life (7.7\u00a0to 17.8 hours). [14]"}
{"id": "article-25088_8", "title": "Metoclopramide -- Administration", "content": "Metoclopramide is generally administered orally in a tablet or solution form.\u00a0The dosage of the tablets and solutions is generally\u00a05\u00a0to 10 mg. It is usually taken before meals and before sleep. However, it can be administered intramuscularly or intravenously in severely nauseous patients; the intravenous route takes effect much more quickly. [13] Parenteral metoclopramide is also 5 mg. Rectal administration is also an option, as is an intraperitoneal injection in patients undergoing peritoneal dialysis. [21] The\u00a0USFDA also approved metoclopramide nasal spray for symptomatic\u00a0relief in adults with acute and recurrent diabetic gastroparesis. The nasal formulation has a unique benefit; it can be absorbed without depending on the\u00a0absorption in the state of gastroparesis,\u00a0thus ensuring the delivery of a therapeutic dose of metoclopramide. [22] Metoclopramide dosing for\u00a0various indications is as follows:", "contents": "Metoclopramide -- Administration. Metoclopramide is generally administered orally in a tablet or solution form.\u00a0The dosage of the tablets and solutions is generally\u00a05\u00a0to 10 mg. It is usually taken before meals and before sleep. However, it can be administered intramuscularly or intravenously in severely nauseous patients; the intravenous route takes effect much more quickly. [13] Parenteral metoclopramide is also 5 mg. Rectal administration is also an option, as is an intraperitoneal injection in patients undergoing peritoneal dialysis. [21] The\u00a0USFDA also approved metoclopramide nasal spray for symptomatic\u00a0relief in adults with acute and recurrent diabetic gastroparesis. The nasal formulation has a unique benefit; it can be absorbed without depending on the\u00a0absorption in the state of gastroparesis,\u00a0thus ensuring the delivery of a therapeutic dose of metoclopramide. [22] Metoclopramide dosing for\u00a0various indications is as follows:"}
{"id": "article-25088_9", "title": "Metoclopramide -- Administration", "content": "Diabetic Gastroparesis: 10 mg orally/IV/IM four times daily for a maximum duration of 12 weeks; max dose is 40 mg daily.\u00a0Start at 5 mg four times daily for geriatric patients. For patients who are poor CYP2D6 metabolizers, give 5 mg four times daily (30 minutes before meals and at bedtime) with a max dose of 20 mg daily. [2]", "contents": "Metoclopramide -- Administration. Diabetic Gastroparesis: 10 mg orally/IV/IM four times daily for a maximum duration of 12 weeks; max dose is 40 mg daily.\u00a0Start at 5 mg four times daily for geriatric patients. For patients who are poor CYP2D6 metabolizers, give 5 mg four times daily (30 minutes before meals and at bedtime) with a max dose of 20 mg daily. [2]"}
{"id": "article-25088_10", "title": "Metoclopramide -- Administration", "content": "GERD (chronic): 10 to 15 mg orally/IM/IV four times daily for a maximum duration of 12 weeks; maximum dose of 60 mg daily. Start at 5 mg four times daily for geriatric patients; max dose 30 mg daily. For patients who are poor CYP2D6 metabolizers, give 5 mg four times daily (30 minutes before meals and at bedtime) or 10 mg three times daily (30 minutes before meals). GERD (intermittent): Up to 20 mg orally/IV/IM\u00a0for one dose before symptoms begin.", "contents": "Metoclopramide -- Administration. GERD (chronic): 10 to 15 mg orally/IM/IV four times daily for a maximum duration of 12 weeks; maximum dose of 60 mg daily. Start at 5 mg four times daily for geriatric patients; max dose 30 mg daily. For patients who are poor CYP2D6 metabolizers, give 5 mg four times daily (30 minutes before meals and at bedtime) or 10 mg three times daily (30 minutes before meals). GERD (intermittent): Up to 20 mg orally/IV/IM\u00a0for one dose before symptoms begin."}
{"id": "article-25088_11", "title": "Metoclopramide -- Administration", "content": "Prophylaxis of Chemotherapy-related Nausea and Vomiting: 1 to 2 mg/kg/dose IV every 2 to 3 hours; the first dose is given 30 minutes before starting chemotherapy, then repeated for two doses every 2 hours, then three doses every 3 hours. Pretreat with diphenhydramine to reduce extrapyramidal symptoms. Metoclopramide is not a first-line agent for this purpose.", "contents": "Metoclopramide -- Administration. Prophylaxis of Chemotherapy-related Nausea and Vomiting: 1 to 2 mg/kg/dose IV every 2 to 3 hours; the first dose is given 30 minutes before starting chemotherapy, then repeated for two doses every 2 hours, then three doses every 3 hours. Pretreat with diphenhydramine to reduce extrapyramidal symptoms. Metoclopramide is not a first-line agent for this purpose."}
{"id": "article-25088_12", "title": "Metoclopramide -- Administration -- Use in Specific Patient Populations", "content": "Patients with Hepatic Impairment: Reduce the dose of metoclopramide in patients with moderate or severe hepatic impairment (Child-Pugh B or C). The recommended dose for diabetic gastroparesis is\u00a05 mg\u00a0four times daily.", "contents": "Metoclopramide -- Administration -- Use in Specific Patient Populations. Patients with Hepatic Impairment: Reduce the dose of metoclopramide in patients with moderate or severe hepatic impairment (Child-Pugh B or C). The recommended dose for diabetic gastroparesis is\u00a05 mg\u00a0four times daily."}
{"id": "article-25088_13", "title": "Metoclopramide -- Administration -- Use in Specific Patient Populations", "content": "Patients with Renal Impairment: In patients with kidney failure, it is generally recommended that metoclopramide maintenance doses be reduced to avoid drug accumulation. [23] Use caution in moderate or severe renal impairment (creatinine clearance<60 mL/minute). In patients with end-stage renal disease requiring\u00a0hemodialysis, the maximum recommended dose is 5 mg twice daily. Lifestyle modification in the form of smaller and more frequent meals is first-line therapy.\u00a0According to the American society of nephrology guidelines, metoclopramide\u00a0can be used at 2.5 mg every four hours in refractory cases. [24]", "contents": "Metoclopramide -- Administration -- Use in Specific Patient Populations. Patients with Renal Impairment: In patients with kidney failure, it is generally recommended that metoclopramide maintenance doses be reduced to avoid drug accumulation. [23] Use caution in moderate or severe renal impairment (creatinine clearance<60 mL/minute). In patients with end-stage renal disease requiring\u00a0hemodialysis, the maximum recommended dose is 5 mg twice daily. Lifestyle modification in the form of smaller and more frequent meals is first-line therapy.\u00a0According to the American society of nephrology guidelines, metoclopramide\u00a0can be used at 2.5 mg every four hours in refractory cases. [24]"}
{"id": "article-25088_14", "title": "Metoclopramide -- Administration -- Use in Specific Patient Populations", "content": "Pregnancy Considerations: Metoclopramide can\u00a0cross the placental barrier. Maternal administration of metoclopramide during delivery can lead to extrapyramidal signs and methemoglobinemia in neonates. According to ACOG(The American College of Obstetricians and Gynecologists) guidelines, metoclopramide should be used only in refractory cases of nausea and vomiting during pregnancy, 5\u00a0to 10 mg every 6\u00a0to 8 hours, orally or intramuscularly, in adequately hydrated patients. The preferred\u00a0pharmacological management is pyridoxine(vitamin B6) or pyridoxine in combination with doxylamine. [25]", "contents": "Metoclopramide -- Administration -- Use in Specific Patient Populations. Pregnancy Considerations: Metoclopramide can\u00a0cross the placental barrier. Maternal administration of metoclopramide during delivery can lead to extrapyramidal signs and methemoglobinemia in neonates. According to ACOG(The American College of Obstetricians and Gynecologists) guidelines, metoclopramide should be used only in refractory cases of nausea and vomiting during pregnancy, 5\u00a0to 10 mg every 6\u00a0to 8 hours, orally or intramuscularly, in adequately hydrated patients. The preferred\u00a0pharmacological management is pyridoxine(vitamin B6) or pyridoxine in combination with doxylamine. [25]"}
{"id": "article-25088_15", "title": "Metoclopramide -- Administration -- Use in Specific Patient Populations", "content": "Breastfeeding Considerations: Metoclopramide is used as a galactagogue, but\u00a0the clinical value of metoclopramide in increasing milk supply is uncertain. A meta-analysis of eight clinical trials\u00a0indicated\u00a0that metoclopramide increased serum prolactin but did not increase milk supply. Metoclopramide use increases the risk of postpartum depression and tardive dyskinesia. Use with caution. [26]", "contents": "Metoclopramide -- Administration -- Use in Specific Patient Populations. Breastfeeding Considerations: Metoclopramide is used as a galactagogue, but\u00a0the clinical value of metoclopramide in increasing milk supply is uncertain. A meta-analysis of eight clinical trials\u00a0indicated\u00a0that metoclopramide increased serum prolactin but did not increase milk supply. Metoclopramide use increases the risk of postpartum depression and tardive dyskinesia. Use with caution. [26]"}
{"id": "article-25088_16", "title": "Metoclopramide -- Adverse Effects", "content": "Adverse effects of metoclopramide use include extrapyramidal symptoms. [27] [28] These include the following: Acute dystonic reactions Torticollis Trismus Opisthotonus Akathisia Dystonia Oculogyric crisis Laryngospasm Hyperprolactinemia Tardive dyskinesia Parkinson symptoms Neuroleptic malignant syndrome Neuroleptic malignant syndrome is a rare adverse effect. [29] It is among the most serious adverse reactions because it manifests as follows: Hyperthermia Lead pipe rigidity Leukocytosis Elevated creatine phosphokinase levels Altered consciousness Symptoms of autonomic instability (potentially) Diaphoresis Tachycardia Incontinence Pallor Irregular blood pressure or pulse Cardiac arrhythmias", "contents": "Metoclopramide -- Adverse Effects. Adverse effects of metoclopramide use include extrapyramidal symptoms. [27] [28] These include the following: Acute dystonic reactions Torticollis Trismus Opisthotonus Akathisia Dystonia Oculogyric crisis Laryngospasm Hyperprolactinemia Tardive dyskinesia Parkinson symptoms Neuroleptic malignant syndrome Neuroleptic malignant syndrome is a rare adverse effect. [29] It is among the most serious adverse reactions because it manifests as follows: Hyperthermia Lead pipe rigidity Leukocytosis Elevated creatine phosphokinase levels Altered consciousness Symptoms of autonomic instability (potentially) Diaphoresis Tachycardia Incontinence Pallor Irregular blood pressure or pulse Cardiac arrhythmias"}
{"id": "article-25088_17", "title": "Metoclopramide -- Adverse Effects", "content": "Thus, any patient on metoclopramide who develops neuroleptic malignant syndrome should have metoclopramide immediately discontinued and undergo treatment with dantrolene. These adverse effects stem from metoclopramide\u2019s anti-dopaminergic mechanism of action. It is important to note that these adverse effects are dose-independent and generally\u00a0reversible following discontinuation of the drug. [30] Furthermore, it is important to keep in mind that oculogyric crises caused by metoclopramide can resemble the following: Seizures Cranial nerve palsies Paroxysmal tonic upward gaze Encephalopathy [31] Metoclopramide-induced hyperprolactinemia can cause\u00a0the following: Gynecomastia Galactorrhea Amenorrhea Impotence Hypogonadism", "contents": "Metoclopramide -- Adverse Effects. Thus, any patient on metoclopramide who develops neuroleptic malignant syndrome should have metoclopramide immediately discontinued and undergo treatment with dantrolene. These adverse effects stem from metoclopramide\u2019s anti-dopaminergic mechanism of action. It is important to note that these adverse effects are dose-independent and generally\u00a0reversible following discontinuation of the drug. [30] Furthermore, it is important to keep in mind that oculogyric crises caused by metoclopramide can resemble the following: Seizures Cranial nerve palsies Paroxysmal tonic upward gaze Encephalopathy [31] Metoclopramide-induced hyperprolactinemia can cause\u00a0the following: Gynecomastia Galactorrhea Amenorrhea Impotence Hypogonadism"}
{"id": "article-25088_18", "title": "Metoclopramide -- Adverse Effects", "content": "In patients with glucose-6-phosphate dehydrogenase deficiency or nicotinamide adenine dinucleotide cytochrome b5 reductase deficiency, metoclopramide can cause methemoglobinemia and sulfhemoglobinemia. [32] [33] Additionally, metoclopramide can increase serum aldosterone levels, potentially causing fluid retention and volume overload. Therefore, it must be used with caution in patients with heart failure or cirrhosis of the liver. [34] Metoclopramide has also been shown to cause a non-thrombocytopenic purpuric rash that subsides upon discontinuation of the drug. [35] Less acute adverse effects of metoclopramide, generally reversible and observed in children, include the following: Sedation Diarrhea [36] Rarer psychiatric side effects that have\u00a0developed following brief\u00a0exposure to metoclopramide include: Panic disorder Major depressive disorder Agoraphobia [37]", "contents": "Metoclopramide -- Adverse Effects. In patients with glucose-6-phosphate dehydrogenase deficiency or nicotinamide adenine dinucleotide cytochrome b5 reductase deficiency, metoclopramide can cause methemoglobinemia and sulfhemoglobinemia. [32] [33] Additionally, metoclopramide can increase serum aldosterone levels, potentially causing fluid retention and volume overload. Therefore, it must be used with caution in patients with heart failure or cirrhosis of the liver. [34] Metoclopramide has also been shown to cause a non-thrombocytopenic purpuric rash that subsides upon discontinuation of the drug. [35] Less acute adverse effects of metoclopramide, generally reversible and observed in children, include the following: Sedation Diarrhea [36] Rarer psychiatric side effects that have\u00a0developed following brief\u00a0exposure to metoclopramide include: Panic disorder Major depressive disorder Agoraphobia [37]"}
{"id": "article-25088_19", "title": "Metoclopramide -- Adverse Effects -- Drug-Drug Interactions", "content": "Reduced efficacy of dopamine agonists(like bromocriptine and cabergoline) [38] Furthermore, metoclopramide can increase serum aspirin levels by increasing the absorption of aspirin, potentially causing salicylate toxicity. [39] In addition to increasing the absorption of aspirin, metoclopramide can also increase serum levels of bupropion and its metabolite\u00a0hydroxybupropion\u00a0because it aids gastric emptying and thus bupropion absorption in the small intestine. [40] This can increase the serum levels of other drugs, given that bupropion and hydroxybupropion, in turn, inhibit the effects of the CYP2D6 metabolic enzyme. [41]", "contents": "Metoclopramide -- Adverse Effects -- Drug-Drug Interactions. Reduced efficacy of dopamine agonists(like bromocriptine and cabergoline) [38] Furthermore, metoclopramide can increase serum aspirin levels by increasing the absorption of aspirin, potentially causing salicylate toxicity. [39] In addition to increasing the absorption of aspirin, metoclopramide can also increase serum levels of bupropion and its metabolite\u00a0hydroxybupropion\u00a0because it aids gastric emptying and thus bupropion absorption in the small intestine. [40] This can increase the serum levels of other drugs, given that bupropion and hydroxybupropion, in turn, inhibit the effects of the CYP2D6 metabolic enzyme. [41]"}
{"id": "article-25088_20", "title": "Metoclopramide -- Adverse Effects -- Drug-Drug Interactions", "content": "Concurrent administration of\u00a0metoclopramide and antipsychotic\u00a0drugs should be avoided due to the potential for additive effects and neuroleptic malignant syndrome(NMS). [42] Metoclopramide\u00a0should not be administered with\u00a0CYP2D6 inhibitors like fluoxetine as there is an increased risk of extrapyramidal symptoms. [43]", "contents": "Metoclopramide -- Adverse Effects -- Drug-Drug Interactions. Concurrent administration of\u00a0metoclopramide and antipsychotic\u00a0drugs should be avoided due to the potential for additive effects and neuroleptic malignant syndrome(NMS). [42] Metoclopramide\u00a0should not be administered with\u00a0CYP2D6 inhibitors like fluoxetine as there is an increased risk of extrapyramidal symptoms. [43]"}
{"id": "article-25088_21", "title": "Metoclopramide -- Contraindications", "content": "Metoclopramide is contraindicated in patients with the following: Known hypersensitivity to metoclopramide or excipients [44] Gastrointestinal bleeding Obstruction Perforation [30] Other contraindications include\u00a0the following: Pheochromocytoma Seizures Depression Parkinson disease", "contents": "Metoclopramide -- Contraindications. Metoclopramide is contraindicated in patients with the following: Known hypersensitivity to metoclopramide or excipients [44] Gastrointestinal bleeding Obstruction Perforation [30] Other contraindications include\u00a0the following: Pheochromocytoma Seizures Depression Parkinson disease"}
{"id": "article-25088_22", "title": "Metoclopramide -- Contraindications", "content": "Metoclopramide is contraindicated in patients with depression because\u00a0it can cause major depressive disorder. [37] It is contraindicated in patients with seizures because it lowers the seizure threshold and can result in longer and more frequent seizures. [45] It is contraindicated in patients with depression and Parkinson disease because of the\u00a0aforementioned adverse effects of major depressive disorder and parkinsonian symptoms. It is contraindicated in pheochromocytoma because it releases catecholamines and can exacerbate pheochromocytoma, causing a hypertensive crisis, which can be treated with phentolamine. [46] [45]", "contents": "Metoclopramide -- Contraindications. Metoclopramide is contraindicated in patients with depression because\u00a0it can cause major depressive disorder. [37] It is contraindicated in patients with seizures because it lowers the seizure threshold and can result in longer and more frequent seizures. [45] It is contraindicated in patients with depression and Parkinson disease because of the\u00a0aforementioned adverse effects of major depressive disorder and parkinsonian symptoms. It is contraindicated in pheochromocytoma because it releases catecholamines and can exacerbate pheochromocytoma, causing a hypertensive crisis, which can be treated with phentolamine. [46] [45]"}
{"id": "article-25088_23", "title": "Metoclopramide -- Contraindications", "content": "US Boxed Warning: Metoclopramide can cause tardive dyskinesia, a serious movement disorder. Tardive dyskinesia risk increases with the total treatment duration and total cumulative exposure. Therefore, avoid\u00a0treatment with metoclopramide tablets for longer than 12 weeks. Discontinue metoclopramide in patients who develop clinical signs or symptoms of tardive dyskinesia. In some patients, symptoms may\u00a0decrease or resolve after metoclopramide is discontinued. [47] [48]", "contents": "Metoclopramide -- Contraindications. US Boxed Warning: Metoclopramide can cause tardive dyskinesia, a serious movement disorder. Tardive dyskinesia risk increases with the total treatment duration and total cumulative exposure. Therefore, avoid\u00a0treatment with metoclopramide tablets for longer than 12 weeks. Discontinue metoclopramide in patients who develop clinical signs or symptoms of tardive dyskinesia. In some patients, symptoms may\u00a0decrease or resolve after metoclopramide is discontinued. [47] [48]"}
{"id": "article-25088_24", "title": "Metoclopramide -- Monitoring", "content": "It is also important to note that the efficacy of metoclopramide can be diminished if the patient takes anticholinergics or narcotic analgesic medications because these drugs decrease the gastric emptying rate. [49] Metoclopramide decreases the absorption rate of drugs\u00a0generally absorbed from the stomach,\u00a0like digoxin,\u00a0while increasing the absorption of drugs absorbed from the small intestine, like cyclosporine. [50] [51]", "contents": "Metoclopramide -- Monitoring. It is also important to note that the efficacy of metoclopramide can be diminished if the patient takes anticholinergics or narcotic analgesic medications because these drugs decrease the gastric emptying rate. [49] Metoclopramide decreases the absorption rate of drugs\u00a0generally absorbed from the stomach,\u00a0like digoxin,\u00a0while increasing the absorption of drugs absorbed from the small intestine, like cyclosporine. [50] [51]"}
{"id": "article-25088_25", "title": "Metoclopramide -- Monitoring", "content": "Metoclopramide is included in the KIDS list (Key Potentially Inappropriate Drugs in Pediatrics), a reference\u00a0tool to identify medications associated with a high risk for adverse drug reactions. Monitor when metoclopramide is used in pediatric patients. [52] Metocloclopramide is also recognized as a potentially inappropriate medication for older adults per the\u00a0American Geriatrics Society 2019 updated Beers criteria. Monitor elderly patients for extrapyramidal symptoms and tardive dyskinesia. [53]", "contents": "Metoclopramide -- Monitoring. Metoclopramide is included in the KIDS list (Key Potentially Inappropriate Drugs in Pediatrics), a reference\u00a0tool to identify medications associated with a high risk for adverse drug reactions. Monitor when metoclopramide is used in pediatric patients. [52] Metocloclopramide is also recognized as a potentially inappropriate medication for older adults per the\u00a0American Geriatrics Society 2019 updated Beers criteria. Monitor elderly patients for extrapyramidal symptoms and tardive dyskinesia. [53]"}
{"id": "article-25088_26", "title": "Metoclopramide -- Toxicity", "content": "The following are the primary symptoms of metoclopramide overdose: Sedation [54] Diarrhea [55] Extrapyramidal adverse effects (particularly tardive dyskinesia) [27]", "contents": "Metoclopramide -- Toxicity. The following are the primary symptoms of metoclopramide overdose: Sedation [54] Diarrhea [55] Extrapyramidal adverse effects (particularly tardive dyskinesia) [27]"}
{"id": "article-25088_27", "title": "Metoclopramide -- Toxicity", "content": "Tardive dyskinesia is an adverse effect, often seen in antipsychotic medications, that generally\u00a0manifests as grimacing, lip-smacking, tongue flicking, and general choreoathetoid movements of the body. [56] Because it can sometimes be irreversible, it is the most threatening potential complication of metoclopramide overdose, and metoclopramide treatment should be discontinued in any patient who develops tardive dyskinesia. Extrapyramidal adverse effects have been\u00a0observed in metoclopramide overdose, particularly in infants and the elderly, who are at the most significant risk. [57] Retrospective analysis has shown that pediatric emergency room visits leading to extrapyramidal symptoms\u00a0can be caused by metoclopramide syrup overdose. [58]", "contents": "Metoclopramide -- Toxicity. Tardive dyskinesia is an adverse effect, often seen in antipsychotic medications, that generally\u00a0manifests as grimacing, lip-smacking, tongue flicking, and general choreoathetoid movements of the body. [56] Because it can sometimes be irreversible, it is the most threatening potential complication of metoclopramide overdose, and metoclopramide treatment should be discontinued in any patient who develops tardive dyskinesia. Extrapyramidal adverse effects have been\u00a0observed in metoclopramide overdose, particularly in infants and the elderly, who are at the most significant risk. [57] Retrospective analysis has shown that pediatric emergency room visits leading to extrapyramidal symptoms\u00a0can be caused by metoclopramide syrup overdose. [58]"}
{"id": "article-25088_28", "title": "Metoclopramide -- Toxicity", "content": "Though there is no specific treatment for metoclopramide overdose, its extrapyramidal effects are among the most common adverse effects. They can be alleviated with anticholinergics like benztropine and antihistamines like diphenhydramine. [59] Supportive therapy is recommended, while dialysis is generally\u00a0ineffective in treating metoclopramide overdose. [23]", "contents": "Metoclopramide -- Toxicity. Though there is no specific treatment for metoclopramide overdose, its extrapyramidal effects are among the most common adverse effects. They can be alleviated with anticholinergics like benztropine and antihistamines like diphenhydramine. [59] Supportive therapy is recommended, while dialysis is generally\u00a0ineffective in treating metoclopramide overdose. [23]"}
{"id": "article-25088_29", "title": "Metoclopramide -- Enhancing Healthcare Team Outcomes", "content": "Metoclopramide is widely used in most hospitals and is an effective drug for gastroparesis and postoperative nausea and vomiting. However, the drug does have several side effects that all healthcare practitioners must be familiar with, so an interprofessional team approach is necessary. The nurse and pharmacist are in a prime position to monitor the drug and, hopefully, reduce its adverse effects by closely monitoring the patient and recommending discontinuation when symptoms arise. Of all the side effects, the most concerning are the extrapyramidal reactions that\u00a0are more likely to occur\u00a0in diabetics, children, seniors, and those already taking antipsychotic\u00a0medications. The risk of developing tardive dyskinesia from metoclopramide varies from 1 to 15%, and the condition is quite debilitating. Hence, before using this drug, the nurse, pharmacist, and prescriber should obtain informed consent from the patient. All patients should be told about the potential for developing dyskinesias before treatment. If the patient has an adverse risk profile, the pharmacist should offer another agent option to the prescriber for consideration.", "contents": "Metoclopramide -- Enhancing Healthcare Team Outcomes. Metoclopramide is widely used in most hospitals and is an effective drug for gastroparesis and postoperative nausea and vomiting. However, the drug does have several side effects that all healthcare practitioners must be familiar with, so an interprofessional team approach is necessary. The nurse and pharmacist are in a prime position to monitor the drug and, hopefully, reduce its adverse effects by closely monitoring the patient and recommending discontinuation when symptoms arise. Of all the side effects, the most concerning are the extrapyramidal reactions that\u00a0are more likely to occur\u00a0in diabetics, children, seniors, and those already taking antipsychotic\u00a0medications. The risk of developing tardive dyskinesia from metoclopramide varies from 1 to 15%, and the condition is quite debilitating. Hence, before using this drug, the nurse, pharmacist, and prescriber should obtain informed consent from the patient. All patients should be told about the potential for developing dyskinesias before treatment. If the patient has an adverse risk profile, the pharmacist should offer another agent option to the prescriber for consideration."}
{"id": "article-25088_30", "title": "Metoclopramide -- Enhancing Healthcare Team Outcomes", "content": "All interprofessional team members are also responsible for communicating concerns with other team members. They must also maintain accurate and updated records of their observations and interventions with the patient so that all team members have the most recent data on the case. Closely monitoring the patient is critical, and the interprofessional team, including clinicians, nursing, and pharmacy, will drive optimal outcomes. [60] [Level 5]", "contents": "Metoclopramide -- Enhancing Healthcare Team Outcomes. All interprofessional team members are also responsible for communicating concerns with other team members. They must also maintain accurate and updated records of their observations and interventions with the patient so that all team members have the most recent data on the case. Closely monitoring the patient is critical, and the interprofessional team, including clinicians, nursing, and pharmacy, will drive optimal outcomes. [60] [Level 5]"}
{"id": "article-25088_31", "title": "Metoclopramide -- Enhancing Healthcare Team Outcomes -- Outcomes", "content": "Metoclopramide has proven valuable in managing\u00a0diabetic gastroparesis, postoperative nausea, and vomiting. However, the potential risk for dyskinesias has led to a re-evaluation of this agent. Experts\u00a0indicate that metoclopramide should be started with the lowest possible\u00a0dose and the shortest duration of time. The drug is effective in the short term, but its CNS\u00a0adverse drug reactions\u00a0are worrisome. [61] [Level 5]", "contents": "Metoclopramide -- Enhancing Healthcare Team Outcomes -- Outcomes. Metoclopramide has proven valuable in managing\u00a0diabetic gastroparesis, postoperative nausea, and vomiting. However, the potential risk for dyskinesias has led to a re-evaluation of this agent. Experts\u00a0indicate that metoclopramide should be started with the lowest possible\u00a0dose and the shortest duration of time. The drug is effective in the short term, but its CNS\u00a0adverse drug reactions\u00a0are worrisome. [61] [Level 5]"}
{"id": "article-25088_32", "title": "Metoclopramide -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Metoclopramide -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}